Combination Low-Dose Tissue-Type Plasminogen Activator Plus Annexin A2 for Improving Thrombolytic Stroke Therapy
نویسندگان
چکیده
Risk of hemorrhagic transformation, incomplete reperfusion, neurotoxicity, and a short treatment time window comprises major challenges for tissue plasminogen activator (tPA) thrombolytic stroke therapy. Improving tPA therapy has become one of the highest priorities in the stroke field. This mini review article focuses on our recent efforts aimed at evaluating a novel combination approach of low-dose tPA plus recombinant annexin A2 (rA2, a tPA, and plasminogen co-receptor), which might enhance tPA thrombolytic efficacy, while reducing its associated complications related to intracerebral hemorrhagic transformation. Results of our experimental studies using a focal embolic stroke model in rats support the feasibility of the combination approach and suggest the potential for successful clinical translation.
منابع مشابه
Annexin A2: a tissue plasminogen activator amplifier for thrombolytic stroke therapy.
Hemorrhagic transformation, incomplete reperfusion, neurotoxicity, and the short treatment time window comprise major challenges for thrombolytic therapy. Improving tissue plasminogen activator therapy has become one of the highest priorities in the stroke field. Recent efforts have been aimed at identifying new strategies that might enhance the thrombolytic efficacy of tissue plasminogen activ...
متن کاملFocal Embolic Cerebral Ischemia in Rats
Improving tissue-type plasminogen activator (tPA) thrombolytic therapy is a high priority in stroke research. The ability of tPA to convert plasminogen efficiently into clot-dissolving plasmin relies on an endogenous fibrinolytic assembly via a triple complex formation of tPA, annexin A2, and plasminogen. Annexin A2 is a cell-surface protein, which, in complex with its binding partner p11, form...
متن کاملA clinical study investigating the three months prognosis of patients with ischemic stroke treated with recombinant tissue plasminogen activator (rt-PA) and its effective factors
Objective: Currently, treating ischemic stroke by intravenous thrombolytic therapy has acceptable results in patients with stroke. This study aimed to evaluate the three months prognosis of patients treated with recombinant tissue plasminogen activator (rt-PA).Methods: This cross-sectional prospective study was conducted on 30 patients with cerebral ischemic stroke with the National Insti...
متن کاملNovel combination therapy of recombinant annexin 2 and low dose recombinant tissue plasminogen activator in embolic rat stroke model: A magnetic resonance imaging study
Introduction. In the treatment of acute phase ischemic stroke, tPA has high risk of hemorrhage which is usually fatal, and the treatment time window is very narrow. Therefore, the search for alternatives to tPA that can reduce hemorrhagic risk and lengthen treatment time window is an urgent priority. The recent studies report recombinant annexin 2 (rAN2) amplifies tPA converted plasmin generati...
متن کاملCerebral hemorrhagic risk of aspirin or heparin therapy with thrombolytic treatment in rabbits.
We studied the incidence of cerebral hemorrhage in an animal model of embolic stroke to determine the safety of aspirin, heparin, and tissue plasminogen activator therapies. We occluded the middle cerebral arteries of rabbits with labeled blood clots and administered either tissue plasminogen activator, heparin, aspirin, tissue plasminogen activator plus aspirin, tissue plasminogen activator pl...
متن کامل